Fig. 1
From: Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
Selection of agonist antibodies against MPL. a Polyclonal phage ELISA for confirming the enrichment of rhMPL-binding phage antibodies of each round of solution-phase panning. b Monoclonal phage ELISA for selecting rhMPL-specific binding antibodies. c BaF3/MPL cell proliferation assay for determining agonistic antibodies. BaF3/MPL cells were incubated with rhTPO (positive control), 2R5, 2R11, or 2R13 over the indicated concentration range. d ELISA for detecting 2R13 binding activity against rhMPL. The EC50 was calculated by fitting the data to a four-parameter logistic model using GraphPad Prism 9. Data are the mean ± SD (n = 3). e Flow cytometric analysis for detecting 2R13 binding specificity in BaF3 and BaF3/MPL cells. f SPR analysis of 2R13. Two-fold serially diluted 2R13 was injected into the captured rhMPL or rmMPL. Kinetic data from a representative experiment were fitted to a 1:1 binding model. The equilibrium dissociation constant (KD) has been presented